Vanguard Group Inc. Has $15.65 Million Stock Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Vanguard Group Inc. lifted its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 6.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,685,009 shares of the company's stock after acquiring an additional 152,117 shares during the period. Vanguard Group Inc. owned about 4.69% of Olema Pharmaceuticals worth $15,654,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. State Street Corp increased its position in Olema Pharmaceuticals by 1.1% in the third quarter. State Street Corp now owns 1,969,963 shares of the company's stock worth $23,521,000 after buying an additional 21,986 shares during the period. Candriam S.C.A. increased its holdings in shares of Olema Pharmaceuticals by 3.0% during the fourth quarter. Candriam S.C.A. now owns 1,551,562 shares of the company's stock valued at $9,046,000 after purchasing an additional 44,798 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Olema Pharmaceuticals by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 332,950 shares of the company's stock valued at $1,941,000 after purchasing an additional 2,189 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in Olema Pharmaceuticals by 80.5% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 212,246 shares of the company's stock worth $1,237,000 after purchasing an additional 94,651 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Olema Pharmaceuticals by 658.7% in the third quarter. JPMorgan Chase & Co. now owns 181,032 shares of the company's stock worth $2,162,000 after purchasing an additional 157,171 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

Olema Pharmaceuticals Trading Up 1.8 %

Shares of NASDAQ OLMA traded up $0.09 during midday trading on Wednesday, reaching $5.05. The company's stock had a trading volume of 116,782 shares, compared to its average volume of 857,581. The company has a 50 day moving average price of $4.20 and a 200 day moving average price of $6.94. Olema Pharmaceuticals, Inc. has a one year low of $2.86 and a one year high of $16.62. The company has a market cap of $345.08 million, a price-to-earnings ratio of -2.31 and a beta of 2.10.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last released its earnings results on Tuesday, March 18th. The company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.12. Research analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on OLMA. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th. JPMorgan Chase & Co. dropped their price target on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating on the stock in a research report on Friday, March 28th. Finally, Oppenheimer restated an "outperform" rating and set a $25.00 price target (down from $30.00) on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.